Graham Capital Management, L.P. Biotechnology

Graham Capital Management, L.P.

$5.08 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
BBIO Bridge Bio Pharma, Inc.	$5.46B	$129,000 0.0% of portfolio	4,725	Q4 2024 Reduced 85.43%
TNGX Tango Therapeutics, Inc.	$214M	$107,000 0.0% of portfolio	34,804	Q4 2024 New
CHRS Coherus Bio Sciences, Inc.	$85.5M	$105,000 0.0% of portfolio	76,300	Q4 2024 Added 11.14%
AUPH Aurinia Pharmaceuticals Inc.	$1.13B	$102,000 0.0% of portfolio	11,409	Q4 2024 New
CRVS Corvus Pharmaceuticals, Inc.	$198M	$95,000 0.0% of portfolio	18,305	Q4 2024 New
TSVT 2seventy Bio, Inc.	$102M	$95,000 0.0% of portfolio	32,426	Q4 2024 Added 130.48%
SGMO Sangamo Therapeutics, Inc	$175M	$95,000 0.0% of portfolio	93,175	Q4 2024 Reduced 40.33%
NKTR Nektar Therapeutics	$174M	$90,000 0.0% of portfolio	96,911	Q4 2024 Added 408.53%
KALV Kal Vista Pharmaceuticals, Inc.	$262M	$88,000 0.0% of portfolio	10,479	Q4 2024 New
ALLO Allogene Therapeutics, Inc.	$312M	$88,000 0.0% of portfolio	41,737	Q4 2024 New
ITOS I Teos Therapeutics, Inc.	$264M	$85,000 0.0% of portfolio	11,126	Q4 2024 New
MREO Mereo Biopharma Group PLC	$359M	$77,000 0.0% of portfolio	22,189	Q4 2024 Added 74.73%
MRSN Mersana Therapeutics, Inc.	$51.5M	$71,000 0.0% of portfolio	49,724	Q4 2024 Added 17.23%
LRMR Larimar Therapeutics, Inc.	$144M	$53,000 0.0% of portfolio	14,078	Q4 2024 New
PYXS Pyxis Oncology, Inc.	$47M	$46,000 0.0% of portfolio	30,287	Q4 2024 New
AVIR Atea Pharmaceuticals, Inc.	$261M	$41,000 0.0% of portfolio	12,511	Q4 2024 New
FATE Fate Therapeutics Inc	$138M	$36,000 0.0% of portfolio	22,342	Q4 2024 New
VXRT Vaxart, Inc.	$88.6M	$35,000 0.0% of portfolio	53,331	Q4 2024 Added 155.8%
VERU Veru Inc.	$45.7M	$34,000 0.0% of portfolio	52,669	Q4 2024 Reduced 56.81%
INZY Inozyme Pharma, Inc.	$51M	$33,000 0.0% of portfolio	12,044	Q4 2024 New
LYEL Lyell Immunopharma, Inc.	$173M	$33,000 0.0% of portfolio	52,136	Q4 2024 New
PBYI Puma Biotechnology, Inc.	$133M	$32,000 0.0% of portfolio	10,732	Q4 2024 New
GOSS Gossamer Bio, Inc.	$144M	$31,000 0.0% of portfolio	34,947	Q4 2024 New
ADAP Adaptimmune Therapeutics PLC	$94.8M	$20,000 0.0% of portfolio	37,195	Q4 2024 Added 195.39%
PGEN Precigen, Inc.	$410M	$15,000 0.0% of portfolio	13,612	Q4 2024 New
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	12,469	Q4 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.